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Short title: 8-year drug survival of TNFis in SpA
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Objective. To evaluate the 8-year survival of the first TNF inhibitor (TNFi) in patients with axial 
spondyloarthritis (axSpA) or psoriatic arthritis (PsA), identify the predictive factors for withdrawal, 
and compare the discontinuation rates for infliximab, etanercept, and adalimumab. 
Methods. We evaluated PsA and axSpA patients treated with a first-line TNFi between 2005 and 
2015 at four Italian tertiary centres. 8-year drug survival was calculated by Kaplan-Meier method 
and risk for discontinuation among treatment groups compared by stratified log-rank test. 
Univariate and multivariate Cox proportional hazard models were developed to examine 
predictors of withdrawal. 
Results. Out of 614 patients (316 axSpA, 298 PsA), 203 received adalimumab, 131 etanercept, and 
280 infliximab, with similar frequencies in axSpA and PsA subgroups. The cumulative 8-year 
retention rate in the whole population was 55.1% (57.2 and 51.9% and for axSpA and PsA, 
respectively; p=NS). No significant differences were observed in drug persistence among individual 
TNFi in either group. Male sex (HR 0.595, 95% CI 0.405-0.875; p=0.008) and concomitant 
methotrexate use (HR 0.648, 95% CI 0.426-0.985; p=0.042) were associated with a lower risk of 
withdrawal in PsA and high baseline BASDAI (HR 0.9842 95% CI 0.9708-0.9980; p=0.028) in axSpA. 
No difference was found in the comparative analysis of reasons for discontinuation between PsA 
and axSpA. 
Conclusion. We reported that the real-life 8-year retention rate of the first TNFi in axSpA and PsA 
is over 50%, with no significant differences between axSpA and PsA and irrespective of the 
individual TNFi.  
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SIGNIFICANCE AND INNOVATION. 
• The 8-year retention rate of first-line TNFi is similar in axSpA and PsA, cumulatively being 
55.2%; 
• Treatment survival is comparable for etanercept, adalimumab, and infliximab in both PsA 
and axSpA; 
• TNFi treatment persistence was associated with male sex and concomitant methotrexate 
use in PsA and a high baseline BASDAI in axSpA. 
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Spondyloarthropathies (SpA) encompass axial spondyloarthritis (axSpA) and psoriatic arthritis 
(PsA) as the major clinical phenotypes (1). The treatment of SpA changed dramatically with the 
advent of biologic drugs (bDMARDs), particularly TNFalpha inhibitors (TNFis) (2). Currently, five 
TNFis (infliximab, adalimumab, etanercept, and more recently golimumab and certolizumab pegol) 
have been licensed for SpA by the US Food and Drug Administration and the European Medicines 
Agency. Despite relevant evidence supporting the short-term TNFi efficacy and safety profile in 
SpA from randomised controlled trials (RCTs) (3,4), data on their long-term effects are limited. 
Moreover, RCTs external validity may be significantly limited by stringent exclusion and inclusion 
criteria, thus decreasing the applicability of results to daily clinical practice (5). Because of these 
issues, large population-based registries are being used in rheumatology to evaluate the long-term 
performance of bDMARDs in a real life setting, despite the possible lack of the controlled 
characteristic of RCTs (6).  
Drug retention may be considered as a reliable indicator of overall treatment effectiveness in 
observational studies, as it is mainly determined by both drug efficacy and safety profile. Although 
many studies from US and European registries have provided abundant data about TNFi drug 
survival in rheumatoid arthritis (RA), retention rates in SpA are limited to 4 years (7-12). To fill this 
gap, we performed a retrospective multicentric study and determined the 8-year retention rate of 
first-line TNFi in a large cohort of real-life patients affected by axSpA and PsA, comparing the 
between-group withdrawal rates for each TNFi (infliximab, etanercept, and adalimumab) and 
evaluating the potential predictors of drug discontinuation and reasons for withdrawal due to 
adverse events. 
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METHODS. 
Data source and patients  
We included patients ≥18 years with a diagnosis by treating rheumatologists of axSpA or PsA, who 
were prescribed a bDMARD between January 2002 and May 2015 in four tertiary rheumatology 
centres. All patients gave their written informed consent in a single registry approved by the local 
Ethics Committees. Demographic features (age, sex, and time since axSpA or PsA diagnosis) and 
therapeutic data (biologic therapy, concomitant sDMARDs and steroids use) were extracted at 
baseline and every 6 months until the database lock on 31st May, 2015. The analysis was carried 
out on patients who received infliximab, etanercept or adalimumab as first-line biologic therapy. 
Moreover, to balance the exposure among the considered biologic drugs, the evaluation was 
limited to the period when all the three TNFis were available in Italy (from January 2005) as a 
setting with similar access to each drug. Exclusion criteria were a previous therapy with a biologic 
agent or the enrollment in a randomized controlled study. Treatments were administered in 
routine care in accordance with international recommendations: TNFis were prescribed according 
to licensed regimen and concomitant sDMARDs or corticosteroids were administered if ordered by 
the referring rheumatologist.  
 
Outcome. 
The main outcome was 8-year drug survival, retrospectively calculated as the time period until the 
definitive treatment interruption or the first missed dose after initiation of TNFi therapy. 
Discontinuations were considered definitive when indicated in the registry or when no 
consecutive re-introduction of treatment was reported. All observations were censored at the last 
registered visit before May 31
st
, 2015. Patients discontinuing TNFi due to pregnancy or inactive 
disease/remission were censored at the date of discontinuation and thus not counted as events in 
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the survival analysis. The reasons for TNFi withdrawal were arrayed into three major categories: 
inefficacy (primary and secondary lack of response), adverse events (AEs), and others (including 
remission, desire for pregnancy, and patient preference). Additional drug survival sub-analyses 
were conducted by stratifying the study population according to diagnosis (axSpA versus PsA) and 
reasons for TNFi replacement.  
Statistical analysis.  
Descriptive statistics were used for continuous variables to calculate mean and standard deviation, 
median and interquartile range. Associations between categorical variables were assessed by chi-
square tests. Differences between treatment groups were analysed by the Kruskal-Wallis test. 
Survival distribution curves were computed by the Kaplan-Meier method and compared by a 
stratified log-rank test. Univariate and multivariate Cox proportional hazard models were 
developed to examine potential predictors of TNFi withdrawals. Separate models were used in 
both PsA and axSpA for overall discontinuation, discontinuation due to adverse events, and 
discontinuation due to inefficacy (primary and secondary lack of response). Our models included 
gender, HLA-B27 positivity (for axSpA), TNFi agent, and concurrent use of MTX (for PsA) as 
categorical variables, whereas age and disease duration at the beginning of TNFi therapy, BASDAI 
(for axSpA), and Disease Activity Score 28 [DAS-28] (for PsA) as continuous variables. Results are 
presented as hazard ratios (HRs) with 95% confidence intervals (95% CI). Statistical analyses were 
performed using SPSS statistical software, version 20.0 (SPSS, Chicago, IL, USA). P values equal to 
or less than 0.05 were considered statistically significant. 
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Our study cohort (n=614) included 316 patients with axSpA (71.5% ankylosing spondylitis and 
28.5% non-radiographic axSpA) and 298 with PsA (4.7% with predominantly axial and 95.3% with 
peripheral involvement) treated with a first-line TNFI between 2005 and 2015. Enrolled patients 
received infliximab (101 in PsA and 179 in axSpA group), adalimumab (108 in PsA and 95 in axSpA 
group), or etanercept (89 in PsA and 42 in axSpA group). The baseline demographic and clinical 
characteristics of the study population are reported in Table 1. No statistically significant 
difference was found among the three treatment subgroups for all the considered baseline 
variables for both axSpA and PsA. 
Drug survival. 
The cumulative 8-year retention rate in the SpA population was 55.1% (51.9 and 57.2% for PsA 
and axSpA, respectively) (Figure 1). No significant differences were found in the overall drug 
survival in PsA compared to axSpA (HR 1.267, 95% CI 0.965 to 1.664; p=0.088). In the PsA 
subgroup, the estimated proportion of patients maintaining infliximab, adalimumab, and 
etanercept was respectively 65.82, 62.3, and 76.4% after 3 years, 56.9, 60.4, and 71.6% after 5 
years, and 44.9, 51.8, and 65.8% after 8 years. Similarly, in the axSpA subgroup the retention rate 
of infliximab, adalimumab, and etanercept was respectively 73.4, 78.4, and 83.7% after 3 years, 
64%, 76.2, and 79.9% after 5 years, and 50.7, 76.2, and 69.2% after 8 years (Figure 2). No 
significant differences emerged in the comparison of drug survival among TNFis in both axSpA 
(p=0.105) and PsA (p=0.142). Infliximab and etanercept showed similar survival rates in PsA and 
axSpA (HR 1.219, 95% CI 0.846 to 1.755; p=0.288; and HR 1.424, 95% CI 0.669 to 3.033; p=0.359, 
respectively), whereas adalimumab showed a significantly higher survival in axSpA than in PsA 
patients (HR 1.810, 95% CI 1.038 to 3.145; p=0.037).  
Page 9 of 27
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
 9 
Reasons for discontinuation. 
Overall, 266 (43.1%) patients (133 [44.6%] PsA and 133 [42.1%] axSpA), stopped the first-line TNFi. 
Detailed causes of withdrawal are reported in Table 2. Discontinuation was due to inefficacy in 
117 (19.1%) patients (67 [22.4%] PsA and 50 [15.8%] axSpA) and due to AEs in 92 (15%) patients 
(47 [15.8%] PsA and 45 [14.2%] axSpA). No differences were observed between axSpA and PsA in 
the risk of drug withdrawal due to inefficacy (HR 1.395, 95% CI 0.967 to 2.013; p=0.075) or AEs (HR 
1.123, 95% CI 0.746 to 1.691; p=0.578). (Figure 3) 
The sub-analysis of reason for discontinuation according to individual TNFi revealed no significant 
difference in the frequency of withdrawal because of both inefficacy and AEs in axSpA and PsA 
subgroups. In particular, etanercept, adalimumab, and infliximab were stopped because of 
inefficacy in 14.6%, 22.2%, and 29.7% (p=0.055) and because of AEs in 15.7%, 11.1%, and 20.8% 
(p=0.664) PsA patients. In the axSpA subgroup the frequency of withdrawal for etanercept, 
adalimumab, and infliximab was 9.5%, 12.6%, and 19% because of inefficacy (p=0.389) and 11.9%, 
7.4%, and 18.4% because of AEs (p=0.122).  
Predictors of drug survival. 
The results from the univariate and multivariate analyses examining predictors of drug 
discontinuation in axSpA and PsA patients are reported in Table 3. Male sex (HR 0.595, 95% CI 
0.405 to 0.875; p=0.008) and concomitant methotrexate use (HR 0.648, 95% CI 0.426 to 0.985; 
p=0.042) were associated with a lower overall risk of withdrawal only in PsA but not in axSpA. 
Baseline high BASDAI was a predictor of drug persistence in axSpA in the univariate model 
although with a minor magnitude (HR 1.016, 95% CI 1.002 to 1.030; p=0.028), whereas high 
baseline DAS28 was not associated with discontinuation in PsA. Disease duration and age did not 
predict the persistence on treatment in both PsA and axSpA patients.  
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We report herein that the long-term retention rates on first-line TNFi in a large cohort of routine 
care SpA patients, comparing adalimumab, etanercept and infliximab after 8 years is 55.1% 
(median time-on-drug 110.68 months), with no statistically significant difference in the 
comparison between PsA (51.9%) and axSpA (57.2%) subgroups or among the individual anti-TNF 
agents.  
To our knowledge, this is the first report evaluating TNFi persistence in a real-life scenario with a 
prolonged follow-up period, whereas the vast majority of previous similar studies have limited the 
observation to 3 years. The overall SpA 3-year survival rate in our sample (68%) is consistent with 
data reported in the Italian cohort Monitornet (66%) (11) and in the Spanish national registry 
BIOBADASER (10) (74%). Moreover, our short-term drug survival according to disease subgroups 
(72 and 64% at 3 years for axSpA and PsA, respectively) are comparable to those previously 
described by other national registries such as the Norwegian NOR-DMARD (77.5 and 77.3% at 1 
year) (13), Danish DANBIO (63 and 57% at 2 years) (7,8), the Spanish BIOBADASER (76 and 73% for 
ankylosing spondylitis [AS] and PsA, respectively, at 3 years) (10), the Italian MonitorNet (69 and 
64% at 3 years) (11), the British BSRBR (59% for PsA at 3 years) (9) and an Italian observational 
cohort (51% for PsA at 4 years) (12). Compared with our 8-year data, previous reports suggested 
that the overall discontinuation rate of the first TNFi is higher during the first period of treatment 
and becomes progressively lower after 3 years, probably linked to the progressive positive 
selection over time of patients presenting a good clinical response without serious AEs. Moreover, 
specific AEs such as infections have been proven to be more frequent in the first phases of TNFi 
treatment, with a subsequent decrease for longer treatments (14,15). However, our data are very 
reassuring in demonstrating the long-term favourable TNFi safety profile for the treatment of SpA 
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since the discontinuation rate because of AEs in our cohort did not increase over time, with a very 
low long-term occurrence of more serious AEs such as malignancies and cardiovascular events. Of 
note, we observed no significant difference in the long-term safety profile of individual anti-TNF 
agents, showing a similar pattern of withdrawal because of AEs. 
The overall retention rate in our SpA cohort was higher compared with similar studies conducted 
in RA (10,11,13,16), including the one we recently reported in a local population of methotrexate 
insufficient responder RA patients (34% at 8 years) (17). Albeit this comparison has several 
limitations, we are convinced that the observed differences may be due to demographical 
features, disease-specific characteristics, such as younger age at onset and less frequent or less 
severe age-related comorbidities, different TNFi dosage and concomitant treatment, or the lack of 
valid and effective alternative options besides TNF blockade in axSpA.  No significant differences 
were found between PsA and axSpA in terms of demographic baseline characteristics and both 
subgroups included patients with long-standing and severe disease, reflecting the real-life scenario 
of TNFi prescription for SpA in daily practice. Despite showing a non-significant trend towards a 
better retention rate in axSpA compared with PsA patients (57.2 versus 52.5% at 8 years), we 
could not confirm the data by Carmona et al in the BIOBADASER registry (10) and by Brocq et al in 
a French cohort (16).  
Predictive factors associated with TNFi retention rate in SpA are still unclear as no observational 
study reported an association between drug continuation and disease duration or disease activity 
at treatment initiation. Younger age has been described as a predictor of TNFi persistence in SpA 
in the BIOBADASER registry (10) and in AS in the DANBIO registry (7), but not in PsA in both the 
BSRBR cohort (9) and the DANBIO registry (8). Similarly, baseline high CRP predicted a better drug 
survival in both AS and PsA patients in the DANBIO (7,8), but not in the BSRBR (9) registry. In our 
cohort age, disease duration, or baseline CRP do not predict drug withdrawal in both overall SpA 
Page 12 of 27
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
 12 
population and individual disease subgroups but baseline disease activity predicts drug retention 
only in the axSpA subgroup. This latter observation may be the result of the different tools used to 
define disease activity, since BASDAI in axSpA provides a more accurate measure compared with 
DAS28 in PsA. Of note, female sex is associated with a lower retention rate in PsA, as previously 
reported (8,9,13), possibly reflecting the less severe and less rapidly progressing PsA in women 
(18). Nonetheless, tender joint count and disease activity scores are generally higher in women, 
mostly due to different pain perception mechanisms or a higher prevalence of fibromyalgia which 
may contribute to the worse impairment of quality of life and an earlier prescription or stopping of 
TNFis (19,20). A similar effect of gender in predicting a worse TNFi drug survival has been 
observed in ankylosing spondylitis from the DANBIO registry (7), whereas in our population female 
sex is not associated with a higher risk of TNFi discontinuation in axSpA. A possible explanation for 
that apparent discrepancy may be the longer follow-up period in our analysis compared to the 
DANBIO registry (8 vs 2 years), as a very recently published prospective study conducted over a 
12-year follow-up period in the Outcome in AS International Study (OASIS) cohort had no gender-
attributable differences in disease activity, clinical response, or functioning over time (21). The 
effect of concomitant MTX in improving TNFi drug survival has been recently demonstrated in 
large cohorts of patients with PsA (22) and axSpA (23). Our analysis confirms these findings only in 
PsA, whereas the small size of axSpA MTX-treated sample did not allow to find any association.    
In the previous experience with the use of TNFi for RA, the majority of reports pointed toward a 
better retention rate of etanercept compared with monoclonal antibodies (17,24,25). On the 
contrary, in the present analysis no major differences were observed with the use of infliximab, 
etanercept and adalimumab. Consistent with previous reports (8), infliximab showed the worse 
retention rate in both subgroups, but in our cohort this trend was not statistically significant. 
Moreover, adalimumab persistence was significantly higher in axSpA compared with PsA. These 
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findings may be explained by considering the frequent coexistence in SpA (especially axSpA) of 
extra-articular manifestations such as uveitis and inflammatory bowel disease, in which TNFi 
monoclonal antibodies have been proven to be more effective than etanercept, affecting drug 
survival.  
The main limitation of the present study is its observational retrospective design without 
randomization. Consequently, patients with a different discontinuation risk could have been 
channelled to a specific drug, producing selection bias and potentially affecting our comparative 
analysis. However, we observed that the treatment subgroups are balanced for both axSpA and 
PsA, with no statistically significant differences in demographic and baseline disease 
characteristics. Moreover, as usual in long-term drug survival analyses, the number of patients at 
risk tends to progressively decrease by time becoming relatively small at the end of the evaluated 
follow-up period, partially influencing the impact of results. On the other side, the most important 
strength is the very long follow-up period, which allowed for the first time the evaluation of 8-year 
retention rate and the long-term comparison in the same cohort of TNFi drug persistence in axSpA 
and PsA patients. 
In conclusion, we report that TNFis in PsA and axSpA cohorts are associated with a high long-term 
retention rate and a good profile of safety. Future analyses in larger population should be 
advocated to confirm our results. 
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Legends to figures. 
Figure 1: Eight-year overall drug survival on first TNF inhibitor in PsA and axSpA patients. 
 
Figure 2: Eight-year drug survival rates by TNF inhibitor in PsA (A) and axSpA (B) subgroups. 
 
Figure 3: Cumulative incidence of discontinuation for inefficacy (A) and adverse events (B) in PsA 
and axSpA subgroups. 
 





ADA, adalimumab; IFX, infliximab; ETN, etanercept; DAS28, disease activity score for 28 joints; 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein. 
 
Table 2: Reasons for discontinuation by TNF inhibitor in PsA and axSpA subgroups. 
ADA, adalimumab; IFX, infliximab; ETN, etanercept. 
 
Table 3: Predictors of treatment failure in patients with PsA and axSpA treated with TNFi. 
ADA, adalimumab; IFX, infliximab; ETN, etanercept; DAS28, disease activity score for 28 joints; 
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Mean age, yrs 47.81 (SD 12.14) 46.63 (SD 14.49) 48.92 (SD 11.21) 47.75 (SD 11.67) 0.424
a
 42.84 (SD 12.08) 41.30 (SD 11.91) 44.20 (SD 11.49) 45.40 (SD 13.54) 0.149
a
 
Mean disease duration, 
yrs 
8.76 (SD 7.72) 9.31 (SD 7.40) 9.04 (SD 7.78) 7.88 (SD 7.93) 0.142
a
 7.21 (SD 7.95) 7.53 (SD 7.80) 6.77 (SD 8.34) 7.04 (SD 7.71) 0.303
a
 
Males (%) 154 (51.67%) 56 (55.44%) 59 (54.62%) 49 (55.05%) 0.993
b
 221 (69.93%) 127 (70.94%) 61 (64.21%) 33 (78.57%) 0.216
b
 
Mean DAS28 4.51 (SD 1.5) 4.61 (SD 1.65) 4.39 (SD 1.37) 4.53 (SD 1.5) 0.729
a
 - - - - - 
Mean BASDAI - - - - - 4.5 (SD 2.1) 4.9 (SD 2.3) 4.1 (SD 2.3) 4.3 (SD 2.0) 0.074
a
 
Mean CRP (mg/dL) 1.53 (SD 1.82) 1.92 (SD 1.93) 1.15 (SD 1.57) 1.5 (SD 1.89) 0.071
a
 1.47 (SD 1.55) 1.62 (SD 1.55) 1.21 (SD 1.51) 1.02 (SD 1.6) 0.166
a
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Table 2. Reasons for discontinuation by TNF inhibitor in PsA and axSpA subgroups 
 PsA axSpA 
 Total IFX ADA ETN Total IFX ADA ETN 
Inefficacy  
    
    
 Primary no response 13 1 8 4 7 4 3 0 
 Secondary no response 54 29 16 9 43 30 9 4 
Adverse events 
     
    
 Cutaneous tissue disease 12 2 6 4 4 0 4 0 
 Hematologic disease 2 0 0 2 2 1 0 1 
 Neuro-psychiatric disease 0 0 0 0 1 0 1 0 
 Death 1 0 0 1 1 1 0 0 
 Cardiovascular system disease 1 1 0 0 0 0 0 0 
 Major infection 3 1 0 2 6 6 0 0 
 TB infection 1 1 0 0 1 1 0 0 
 Malignancy 6 3 1 2 2 1 0 1 
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 Infusion/Injection reaction 17 13 2 2 25 23 1 1 
 Hepatic toxicity 2 0 2 0 0 0 0 0 
 Ocular disease 2 0 1 1 3 0 1 2 
Other 
     
    
 Lost at follow-up 7 6 0 1 23 17 5 1 
 Remission 7 2 3 2 9 6 2 1 
 Compliance 2 0 2 0 2 2 0 0 
 Pregnancy 3 0 1 2 4 3 1 0 
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Table 3. Predictors of treatment failure in patients with PsA and axSpA treated with TNFi. 
 Univariate analysis Multivariate analysis 
 HR 95% CI HR 95% CI 
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 Adalimumab 1.1 1.2 
 Infliximab 1.7 1.7 
 Female Gender 1.1 1.0 
 Disease duration 1.0 1 
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Figure 1: Eight-year overall drug survival on first TNF inhibitor in PsA and axSpA patients.  
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Figure 2: Eight-year drug survival rates by TNF inhibitor in PsA (A) and axSpA (B) subgroups.  
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Figure 3: Cumulative incidence of discontinuation for inefficacy (A) and adverse events (B) in PsA and axSpA 
subgroups.  
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